SB 5921
In CommitteeSenate
Psilocybin
Concerning psilocybin.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill establishes a regulated medical psilocybin program in Washington State, allowing licensed clinicians to authorize psilocybin treatment for adults with serious or treatment-resistant conditions, under supervision of the Department of Health. It creates licensing for producers and clinicians, sets safety and training standards, and provides legal protections for participants acting within the program.
- Creates the Washington Medical Psilocybin Act and a new program within the Department of Health to regulate medical use of psilocybin.
- Allows clinicians (with prescribing authority and state-approved training) to authorize and administer or supervise administration of psilocybin to qualified patients (age 18+) for conditions they determine are appropriate.
- Establishes a licensing system for producers (who grow, process, and test psilocybin) and clinicians, with requirements for training, background checks, secure storage, and recordkeeping.
- Permits two types of treatment: inpatient medical services (preparation, administration, and integration in a clinical setting) and outpatient microdosing (with clinician authorization and follow-up).
- Exempts participants in the program from arrest or prosecution for psilocybin-related offenses, but explicitly excludes synthetic psilocybin, use by minors, and use in animals.
- Requires a secure electronic registry to track authorizations and prevent duplicate prescriptions, with strict confidentiality rules and annual public reporting on program use and compliance.
Who is affected
- Qualified patients — Must be at least 18 years old, have a diagnosis determined by a clinician as appropriate for psilocybin treatment, and receive care through an approved clinician in a regulated setting.
- Clinicians — Must hold an active, unrestricted license to prescribe controlled substances, complete department-approved training (including on psilocybin, trauma-informed care, and managing adverse reactions), and pass a criminal background check to participate.
- Producers — Must be licensed by the department to grow, process, test, and package psilocybin products for clinicians; must comply with food safety, security, and recordkeeping rules, and may not sell to third-party pharmacies or intermediaries.
- Washington State Department of Health — Will oversee licensing, training, safety protocols, data collection, and enforcement for the program; will issue licenses, conduct audits, and publish annual reports on program use and compliance.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
The bill establishes a medically supervised, legal pathway for psilocybin treatment for adults with serious or treatment-resistant conditions, potentially improving access to evidence-based care for conditions like treatment-resistant depression, PTSD, and end-of-life anxiety — conditions with high unmet need and limited current options.
HealthcarePeopleRef: Sec. 4(1)-(4); Sec. 11(1)(a)Mandates for clinician training (including trauma-informed care and adverse reaction management) and secure storage protocols enhance patient safety and reduce risk of misuse or harm, supporting responsible clinical integration.
HealthcarePeopleRef: Sec. 9(2)(b); Sec. 11(1)(a)The bill creates a centralized, secure electronic registry to prevent duplicate prescriptions and support oversight, while requiring annual public reporting — promoting transparency and data-driven program evaluation without imposing new local administrative burdens.
Local GovernmentRef: Sec. 11(2); Sec. 11(5)The bill explicitly decriminalizes program-compliant psilocybin use for participants, protecting patients and clinicians from arrest or prosecution, and clarifies that psilocybin used in the program is not contraband — reducing legal risks for participants.
Rights & LibertiesRef: Sec. 4(2)(b); Sec. 11(1)(a)The program creates a new regulated industry for producers and clinicians, potentially generating new jobs and economic activity in licensed clinical and manufacturing sectors — though benefits may be concentrated among larger operators due to compliance costs.
Business & EmploymentPeopleRef: Sec. 11(1)(a); Sec. 11(1)(c)
Potential Concerns (5)
The bill creates a new licensing and fee-based regulatory framework for clinicians and producers, requiring participants to cover full program costs through user fees. While this ensures fiscal neutrality for the state, it may create financial barriers for small-scale clinicians (e.g., solo practitioners, rural providers) and limit access in underserved areas due to administrative burden and compliance costs.
HealthcarePeopleRef: Sec. 9(3); Sec. 10The bill explicitly excludes use by minors and animals, but does not establish robust safeguards against diversion or unauthorized access to psilocybin by minors in households, especially given that clinicians may dispense products directly to patients without pharmacy oversight. This could increase risk of accidental or intentional minor exposure.
Public SafetyPeopleRef: Sec. 4(6); Sec. 11(1)(a)The bill provides legal protections for participants (patients, clinicians, producers) acting within the program, exempting them from arrest or prosecution for psilocybin-related offenses. However, these protections are limited to program-compliant conduct and do not extend to off-program use or possession, maintaining existing criminal penalties outside the regulated framework.
Rights & LibertiesRef: Sec. 4(4); Sec. 11(5)The bill does not impose new mandates on local governments, but allows them to enact ordinances decriminalizing psychedelic substances or deprioritizing enforcement — preserving local autonomy while avoiding conflict with state program rules.
Local GovernmentRef: Sec. 11(5)The licensing structure and food-safety requirements (e.g., Department of Agriculture licensing for producers) may disproportionately burden small-scale producers and limit market entry, as compliance costs (e.g., secure storage, testing, recordkeeping) favor larger, better-resourced operators.
Business & EmploymentPeopleRef: Sec. 9(3); Sec. 11(1)(a)
Who Is Most Affected
Patients with serious or treatment-resistant conditions (e.g., depression, PTSD, end-of-life distress) may gain access to a novel, evidence-based therapy under clinical supervision, potentially improving outcomes where conventional treatments have failed.
Clinicians (e.g., psychiatrists, physicians, nurse practitioners) gain legal authority to offer psilocybin therapy, but must complete state-approved training, pass background checks, and comply with strict recordkeeping and storage requirements — adding administrative burden but expanding clinical scope.
Producers face new licensing, food-safety, and testing requirements, which may favor larger, well-capitalized manufacturers over small-scale or home-based producers — creating barriers to entry but also formalizing a previously unregulated market.
The Department of Health gains new regulatory authority and funding flexibility (via user fees), enabling it to build a new program infrastructure; however, this also adds operational responsibilities and potential resource strain in early implementation years.